Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04277884 | Firibastat in Treatment-resistant Hypertension | PHASE3 | COMPLETED | 515 | — | — | Jun 25, 2020 | Sep 20, 2022 | Oct 20, 2022 | 20 | United States, Czechia +4 |
Automatic Office Blood Pressure measurement
| Arm | Type | Description |
|---|---|---|
| Firibastat | EXPERIMENTAL | Capsules |
| Placebo | PLACEBO_COMPARATOR | Matching capsules |
| Name | Type | Description |
|---|---|---|
| Firibastat | DRUG | Oral administration 2×250 mg capsules bid |
| Placebo | DRUG | Oral administration 2 capsules bid |
Inclusion Criteria: * Men and women ≥18 years of age at Screening * Diagnosis of primary HTN for at least 6 months prior to Screening Exclusion Criteria: * Known or suspected secondary HTN (eg, hyperaldosteronism, renovascular HTN, pheochromocytoma, Cushing's disease). * Automated office SBP \>18...